Antigen incorporated in virus-like particles is delivered to specific dendritic cell subsets that induce an effective antitumor immune response in vivo

Journal of Immunotherapy

Volumn 36, Issue 1, 2013, Pages 11-19

  Li, Kunyu ^a   Peers Adams, Amanda ^a   Win, Stephanie J ^a   Scullion, Sarah ^a   Wilson, Michelle ^a   Young, Vivienne L ^a   Jennings, Paula ^a   Ward, Vernon K ^a   Baird, Margaret A ^a   Young, Sarah L ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

cancer immunotherapy; dendritic cells; RHDV; T cells; virus like particle

Indexed keywords

ANTIGEN GP33C; ANTIGEN GP33R; CANCER VACCINE; LANGERIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IN VIVO STUDY; LAGOVIRUS; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VIRUS LIKE AGENT;

ANIMALS; ANTIGENS, VIRAL; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; HEMORRHAGIC DISEASE VIRUS, RABBIT; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; PEPTIDES;

EID: 84871922327     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182787f5e     Document Type: Article

References (36)

1. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell basedvaccines: progress in immunotherapy studies for prostatecancer. J Urol. 2004;172:2532-2538 (Pubitemid 39507464)
2. Lesterhuis WJ, de Vries IJ, Adema GJ, et al. Dendritic cellbasedvaccines in cancer immunotherapy: an update on clinicaland immunological results. Ann Oncol. 2004;15(suppl):iv145-iv151 (Pubitemid 39585327)
3. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine(DTIC) versus vaccination with autologous peptide-pulseddendritic cells (DC) in first-line treatment of patients withmetastatic melanoma: a randomized phase III trial of the DCstudy group of the DeCOG. Ann Oncol. 2006;17:563-570
4. Noad R, Roy P. Virus-like particles as immunogens. TrendsMicrobiol. 2003;11:438-444 (Pubitemid 37101484)
5. Martin FB, Gary TJ. Virus-like particles: combining innateand adaptive immunity for effective vaccination. In: StefanHEK, ed. Novel Vaccination Strategies. Wiley-VCH VerlagGmbH & Co. KGaA, Weinheim, Germany: 2004:415-432
6. Chasey D. Rabbit haemorrhagic disease: the new scourge ofOryctolagus cuniculus. Lab Anim. 1997;31:33-44 (Pubitemid 27075585)
7. Peacey M, Wilson S, Baird MA, et al. Versatile RHDVvirus-like particles: incorporation of antigens by geneticmodification and chemical conjugation. Biotechnol Bioeng.2007;98:968-977 (Pubitemid 350205574)
8. Peacey M, Wilson S, Perret R, et al. Virus-like particles fromrabbit hemorrhagic disease virus can induce an anti-tumorresponse. Vaccine. 2008;26:5334-5337
9. Win SJ, Ward VK, Dunbar PR, et al. Cross-presentation ofepitopes on virus-like particles via the MHC I receptorrecycling pathway. Immunol Cell Biol. 2011;89:681-688
10. Kyburz D, Aichele P, Speiser DE, et al. T cell immunity after aviral infection versus T cell tolerance induced by soluble viralpeptides. Eur J Immunol. 1993;23:1956-1962 (Pubitemid 23236793)
11. Kissenpfennig A, Henri S, Dubois B, et al. Dynamics andfunction of Langerhans cells in vivo: dermal dendritic cellscolonize lymph node areas distinct from slower migratingLangerhans cells. Immunity. 2005;22:643-654 (Pubitemid 40719199)
12. Hermans IF, Ritchie DS, Daish A, et al. Impaired ability ofMHC class II-/-dendritic cells to provide tumor protectionis rescued by CD40 ligation. J Immunol. 1999;163:77-81
13. McKee SJ, Young VL, Clow F, et al. Virus-like particles andalpha-galactosylceramide form a self-adjuvanting compositeparticle that elicits anti-tumor responses. J Control Release.2012;159:338-345
14. Baird M, Wilson R, Young L, et al. Bystander help within apolyepitope DNA vaccine improves immune responses toinfluenza antigens. Scand J Immunol. 2004;60:363-371 (Pubitemid 39331492)
15. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor4-dependent contribution of the immune system to anticancerchemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059 (Pubitemid 47517504)
16. Heo Y, Parsons PJ, Lawrence DA. Lead differentially modifiescytokine production in vitro and in vivo. Toxicol ApplPharmacol. 1996;138:149-157 (Pubitemid 26159605)
17. Kyritsis C, Gorbulev S, Hutschenreiter S, et al. Molecularmechanism and structural aspects of transporter associatedwith antigen processing inhibition by the cytomegalovirusprotein US6. J Biol Chem. 2001;276:48031-48039
18. Gobert M, Treilleux I, Bendriss-Vermare N, et al. RegulatoryT cells recruited through CCL22/CCR4 are selectively activatedin lymphoid infiltrates surrounding primary breasttumors and lead to an adverse clinical outcome. Cancer Res.2009;69:2000-2009
19. Farrand KJ, Dickgreber N, Stoitzner P, et al. Langerin+CD8alpha+ dendritic cells are critical for cross-priming andIL-12 production in response to systemic antigens. J Immunol.2009;183:7732-7742
20. Schirmbeck R, Bohm W, Reimann J. Virus-like particlesinduce MHC class I-restricted T-cell responses. Lessonslearned from the hepatitis B small surface antigen. Intervirology.1996;39:111-119
21. Akahata W, Yang ZY, Andersen H, et al. A virus-like particlevaccine for epidemic Chikungunya virus protects nonhumanprimates against infection. Nat Med. 2010;16:334-338
22. Paliard X, Liu Y,Wagner R, et al. Priming of strong, broad, andlong-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cellsafter administration of a virus-like particle vaccine in rhesusmacaques. AIDS Res Hum Retroviruses. 2000;16:273-282 (Pubitemid 30111963)
23. Murata K, Lechmann M, Qiao M, et al. Immunization withhepatitis C virus-like particles protects mice from recombinanthepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA.2003;100:6753-6758 (Pubitemid 36666652)
24. Sigal LJ, Rock KL. Bone marrow-derived antigen-presentingcells are required for the generation of cytotoxic T lymphocyteresponses to viruses and use transporter associated withantigen presentation (TAP)-dependent and-independent pathwaysof antigen presentation. J Exp Med. 2000;192:1143-1150
25. Alatery A, Siddiqui S, Chan M, et al. Cross, but not direct,presentation of cell-associated virus antigens by spleen macrophagesis influenced by their differentiation state. Immunol CellBiol. 2010;88:3-12
26. Heit A, Huster KM, Schmitz F, et al. CpG-DNA aided crossprimingby cross-presenting B cells. J Immunol. 2004;172:1501-1507 (Pubitemid 38116793)
27. Bedoui S, Whitney PG, Waithman J, et al. Cross-presentationof viral and self antigens by skin-derived CD103+dendritic cells. Nat Immunol. 2009;10:488-495
28. McDonnell AM, Prosser AC, van Bruggen I, et al. CD8alpha+DC are not the sole subset cross-presenting cell-associated tumorantigens from a solid tumor. Eur J Immunol. 2010;40:1617-1627
29. Klinman DM, Barnhart KM, Conover J. CpG motifs asimmune adjuvants. Vaccine. 1999;17:19-25
30. de Brito C, Tomkowiak M, Ghittoni R, et al. CpG promotescross- presentation of dead cell-associated antigens by pre-CD8alpha+ dendritic dells. J Immunol. 2011;186:1503-1511
31. Bryan JT. Developing an HPV vaccine to prevent cervicalcancer and genital warts. Vaccine. 2007;25:3001-3006 (Pubitemid 46482731)
32. LoBue AD, Thompson JM, Lindesmith L, et al. Alphavirusadjuvantednorovirus-like particle vaccines: heterologous,humoral, and mucosal immune responses protect againstmurine norovirus challenge. J Virol. 2009;83:3212-3227
33. Wang BZ, Xu R, Quan FS, et al. Intranasal immunization withinfluenza VLPs incorporating membrane-anchored flagellin inducesstrong heterosubtypic protection. PLoS One. 2010;5:e13972
34. Win SJ, McMillan DG, Errington-Mais F, et al. Enhancing theimmunogenicity of tumour lysate-loaded dendritic cell vaccinesby conjugation to virus-like particles. Br J Cancer. 2012;106:92-98
35. DuPage M, Cheung AF, Mazumdar C, et al. Endogenous Tcell responses to antigens expressed in lung adenocarcinomasdelay malignant tumor progression. Cancer Cell. 2011;19:72-85
36. Gilboa E. The makings of a tumor rejection antigen. Immunity.1999;11:263- 270 (Pubitemid 29463234)